| Elizabeth Ann Ottney, DO | |
|
7029 E Russell St, Mesa, AZ 85207-0996 | |
| (270) 348-2215 | |
| Not Available |
| Full Name | Elizabeth Ann Ottney |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 27 Years |
| Location | 7029 E Russell St, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154397933 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 02685 (Kentucky) | Secondary |
| 207Q00000X | Family Medicine | 4208 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Dignity Health Arizona General Hospital | Mesa, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tec Emergency Physicians Of Arizona, Llc | 6204256084 | 111 |
News Archive
Collaborating with researchers from the Northwestern University Feinberg School of Medicine in Chicago, a research team at Wayne State University's School of Medicine led by Kezhong Zhang, Ph.D., has contributed to an important discovery in the inflammatory stress mechanism and specific inhibitor for the treatment of rheumatoid arthritis.
Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg.
Officials from the Healthcare Leadership Council, a coalition of health insurers, academics, hospitals and other health care groups, proposed using Medicaid and SCHIP funds to purchase private coverage for uninsured U.S. residents, CQ HealthBeat reports.
Challenging long-held notions that osteoarthritis is a result mainly of wear and tear on the joints, researchers led by Dr. William H. Robinson of the Department of Veterans Affairs Palo Alto Health Care System and Stanford University have provided new insights into the immune-system changes that may trigger cartilage breakdown.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
› Verified 9 days ago
| Entity Name | Emergency Physicians Southwest Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912053752 PECOS PAC ID: 2264538529 Enrollment ID: O20070502000382 |
News Archive
Collaborating with researchers from the Northwestern University Feinberg School of Medicine in Chicago, a research team at Wayne State University's School of Medicine led by Kezhong Zhang, Ph.D., has contributed to an important discovery in the inflammatory stress mechanism and specific inhibitor for the treatment of rheumatoid arthritis.
Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg.
Officials from the Healthcare Leadership Council, a coalition of health insurers, academics, hospitals and other health care groups, proposed using Medicaid and SCHIP funds to purchase private coverage for uninsured U.S. residents, CQ HealthBeat reports.
Challenging long-held notions that osteoarthritis is a result mainly of wear and tear on the joints, researchers led by Dr. William H. Robinson of the Department of Veterans Affairs Palo Alto Health Care System and Stanford University have provided new insights into the immune-system changes that may trigger cartilage breakdown.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
› Verified 9 days ago
| Entity Name | Quantum Healthcare Medical Associates Of Arizona Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821391269 PECOS PAC ID: 5597946350 Enrollment ID: O20110228000065 |
News Archive
Collaborating with researchers from the Northwestern University Feinberg School of Medicine in Chicago, a research team at Wayne State University's School of Medicine led by Kezhong Zhang, Ph.D., has contributed to an important discovery in the inflammatory stress mechanism and specific inhibitor for the treatment of rheumatoid arthritis.
Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg.
Officials from the Healthcare Leadership Council, a coalition of health insurers, academics, hospitals and other health care groups, proposed using Medicaid and SCHIP funds to purchase private coverage for uninsured U.S. residents, CQ HealthBeat reports.
Challenging long-held notions that osteoarthritis is a result mainly of wear and tear on the joints, researchers led by Dr. William H. Robinson of the Department of Veterans Affairs Palo Alto Health Care System and Stanford University have provided new insights into the immune-system changes that may trigger cartilage breakdown.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
› Verified 9 days ago
| Entity Name | Emergency Group Of Arizona Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215275433 PECOS PAC ID: 1355596644 Enrollment ID: O20130313000442 |
News Archive
Collaborating with researchers from the Northwestern University Feinberg School of Medicine in Chicago, a research team at Wayne State University's School of Medicine led by Kezhong Zhang, Ph.D., has contributed to an important discovery in the inflammatory stress mechanism and specific inhibitor for the treatment of rheumatoid arthritis.
Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg.
Officials from the Healthcare Leadership Council, a coalition of health insurers, academics, hospitals and other health care groups, proposed using Medicaid and SCHIP funds to purchase private coverage for uninsured U.S. residents, CQ HealthBeat reports.
Challenging long-held notions that osteoarthritis is a result mainly of wear and tear on the joints, researchers led by Dr. William H. Robinson of the Department of Veterans Affairs Palo Alto Health Care System and Stanford University have provided new insights into the immune-system changes that may trigger cartilage breakdown.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
› Verified 9 days ago
| Entity Name | Arizona Acute Medical Services 1 Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154860674 PECOS PAC ID: 6204113970 Enrollment ID: O20170505001284 |
News Archive
Collaborating with researchers from the Northwestern University Feinberg School of Medicine in Chicago, a research team at Wayne State University's School of Medicine led by Kezhong Zhang, Ph.D., has contributed to an important discovery in the inflammatory stress mechanism and specific inhibitor for the treatment of rheumatoid arthritis.
Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg.
Officials from the Healthcare Leadership Council, a coalition of health insurers, academics, hospitals and other health care groups, proposed using Medicaid and SCHIP funds to purchase private coverage for uninsured U.S. residents, CQ HealthBeat reports.
Challenging long-held notions that osteoarthritis is a result mainly of wear and tear on the joints, researchers led by Dr. William H. Robinson of the Department of Veterans Affairs Palo Alto Health Care System and Stanford University have provided new insights into the immune-system changes that may trigger cartilage breakdown.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
› Verified 9 days ago
| Entity Name | Tec Emergency Physicians Of Arizona, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245772870 PECOS PAC ID: 6204256084 Enrollment ID: O20201016000157 |
News Archive
Collaborating with researchers from the Northwestern University Feinberg School of Medicine in Chicago, a research team at Wayne State University's School of Medicine led by Kezhong Zhang, Ph.D., has contributed to an important discovery in the inflammatory stress mechanism and specific inhibitor for the treatment of rheumatoid arthritis.
Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg.
Officials from the Healthcare Leadership Council, a coalition of health insurers, academics, hospitals and other health care groups, proposed using Medicaid and SCHIP funds to purchase private coverage for uninsured U.S. residents, CQ HealthBeat reports.
Challenging long-held notions that osteoarthritis is a result mainly of wear and tear on the joints, researchers led by Dr. William H. Robinson of the Department of Veterans Affairs Palo Alto Health Care System and Stanford University have provided new insights into the immune-system changes that may trigger cartilage breakdown.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Ann Ottney, DO 7029 E Russell St, Mesa, AZ 85207-0996 Ph: (270) 348-2215 | Elizabeth Ann Ottney, DO 7029 E Russell St, Mesa, AZ 85207-0996 Ph: (270) 348-2215 |
News Archive
Collaborating with researchers from the Northwestern University Feinberg School of Medicine in Chicago, a research team at Wayne State University's School of Medicine led by Kezhong Zhang, Ph.D., has contributed to an important discovery in the inflammatory stress mechanism and specific inhibitor for the treatment of rheumatoid arthritis.
Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg.
Officials from the Healthcare Leadership Council, a coalition of health insurers, academics, hospitals and other health care groups, proposed using Medicaid and SCHIP funds to purchase private coverage for uninsured U.S. residents, CQ HealthBeat reports.
Challenging long-held notions that osteoarthritis is a result mainly of wear and tear on the joints, researchers led by Dr. William H. Robinson of the Department of Veterans Affairs Palo Alto Health Care System and Stanford University have provided new insights into the immune-system changes that may trigger cartilage breakdown.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
› Verified 9 days ago
Dr. Jose Rapanan Jr., DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10032 E Southern Ave, Mesa, AZ 85209 Phone: 480-351-2850 | |
Jennifer Christine Fendler, NP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 924 N Country Club Dr, Mesa, AZ 85201 Phone: 480-601-3528 | |
George Ting, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1111 N Stapley Dr, Mesa, AZ 85203 Phone: 480-464-8500 | |
Dr. Thomas P Porter, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1950 S Country Club Dr, Mesa, AZ 85210 Phone: 480-969-1446 Fax: 480-969-9105 | |
Dana S Farris, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10238 E Hampton Ave Ste 506, Mesa, AZ 85209 Phone: 480-834-7546 Fax: 480-833-8313 | |
Nancy Mucha, CNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2843 N 89th St, Mesa, AZ 85207 Phone: 480-396-3482 | |
Ryan Elisabeth Romo, Family Medicine Medicare: Medicare Enrolled Practice Location: 1705 W Main St, Mesa, AZ 85201 Phone: 877-809-5092 |